PTC Therapeutics, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
PTC Therapeutics, Inc. (PTCT) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of -$622.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-02-19
- PTC Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2024-12-31 was $0.00.
- PTC Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2019-09-30 was $0.00.
- PTC Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2019-06-30 was $0.00.
- PTC Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2019-03-31 was $0.00.
- PTC Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2024 was -$622.00K.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$622.00K 10-K · filed 2026-02-19 | ||
| 2024-09-30 | -$622.00K 10-Q · filed 2025-11-04 | |||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $0.00 derived: sum of 2 quarters · filed 2019-10-30 | $0.00 10-Q · filed 2019-10-30 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $0.00 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-02 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $0.00 10-Q · filed 2018-11-05 | ||
| 2018-06-30 | $0.00 10-Q · filed 2018-08-07 | |||
| 2017-12-31 | $0.00 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |